Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

NCT06973629 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis

Interventions

BIOLOGICAL: Debamestrocel - MSC-NTF (NurOwn)
BIOLOGICAL: Placebo

Sponsor

Brainstorm-Cell Therapeutics